leadf
logo-loader
viewInnoCan Pharma
(
CSE:INNO
)

Full interview: Innocan Pharma plans to collaborate with Tel Aviv University to find treatment for COVID-19

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver to bring news the company has entered into a sponsored research agreement with Ramot at Tel Aviv University to collaborate with Tel Aviv University to develop a novel, revolutionary approach to treating COVID-19 by using Cannabidiol loaded Exosomes.

Bincovich tells Proactive this will work in Phases and she discusses what the first part will look like and why they feel CBD could be effective in treating the Corona Virus.

Quick facts: InnoCan Pharma

Follow
CSE:INNO

Price: 1 CAD

Market Cap: $221.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Marble Financial’s subsidiary Inverite Verification records 80,000 monthly...

Marble Financial CEO Karim Nanji joined Steve Darling from Proactive to share news its subsidiary, Inverite Verification has reported achieved record growth and transaction volume milestones. Nanji telling Proactive in August the company surpassed 80,000 monthly transactions and recorded an...

8 hours, 49 minutes ago

2 min read